AYTU — Aytu BioPharma, Inc.
$1.78
$-0.01 (-0.56%)
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT A central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age.
Market Cap
$19.34M
Forward P/E
11.5x
52-Week Range
N/A
AYTU Price History
Revenue vs. Net Income
$57.6M
Revenue · FY2026
Annual. Net margin is shown under each year.
Free Cash Flow
$3.3M
FCF · FY2026
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-24.5%
ROCE · FY2026
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
1.5x
Assets ÷ liabilities · FY2026
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.1%
CapEx · FY2026
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+96.2%
Dilution · FY2026
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
